NEWS
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
IGC Pharma has announced promising preclinical data for its drug candidate TGR-63, targeting Alzheimer’s disease. Studies indicate that TGR-63 can cross the blood-brain barrier, a critical challenge in treating Alzheimer's, as confirmed through mass spectrometry and an octanol-water assay. The drug also demonstrated a favorable safety profile, with no adverse effects observed in mice after eight months. The company plans to advance TGR-63 into clinical trials, presenting it as a potential safer alternative to existing treatments. IGC is also exploring other disease targets using AI-driven analyses.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment